U.S. regulators gave GlaxoSmithKline's ($GSK) Advair the green light a decade and a half ago, paving the way for a long reign that saw the med grow to more than $8 ...
LONDON (Reuters) - Denmark has approved the sale of a generic copy of GlaxoSmithKline's $8 billion-a-year inhaled lung drug Advair, threatening future sales of the British firm's biggest product.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback